Analyzing MediWound (NASDAQ:MDWD) & Jinhua Marine Biological (OTCMKTS:JNMB)

Jinhua Marine Biological (OTCMKTS:JNMB) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Profitability

This table compares Jinhua Marine Biological and MediWound’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jinhua Marine Biological	N/A	N/A	N/A
MediWound	-64.24%	-21.67%	-10.23%

Insider & Institutional Ownership

46.8% of MediWound shares are owned by institutional investors. 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Jinhua Marine Biological and MediWound’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jinhua Marine Biological	N/A	N/A	N/A	N/A	N/A
MediWound	$20.14 million	8.48	-$6.72 million	($1.38)	-13.33

Jinhua Marine Biological has higher earnings, but lower revenue than MediWound.

Analyst Ratings

This is a summary of recent ratings and price targets for Jinhua Marine Biological and MediWound, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jinhua Marine Biological	0	0	0	0	N/A
MediWound	0	0	2	0	3.00

MediWound has a consensus target price of $29.00, suggesting a potential upside of 57.69%. Given MediWound’s higher possible upside, analysts clearly believe MediWound is more favorable than Jinhua Marine Biological.

Summary

MediWound beats Jinhua Marine Biological on 5 of the 8 factors compared between the two stocks.

About Jinhua Marine Biological

Jinhua Marine Biological (USA), Inc. develops allopelagic materials, biological medicines, pesticides, environmental protection products, and products for the home. It offers health products, including Xiduoan, which is used for strengthening and adjusting the immune system. The company also introduces advanced wastewater treatment technology, as well as develops environmental protection projects, including industry/urban wastewater treatment. This business was pursued in three areas: the development, manufacture, distribution and sale of ERGOS Systems directly by the Company; consulting services, and the delivery of marketing and other services to ERGOS network providers.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.